New Data Show Preemptive Treatment May Significantly Reduce Skin Toxicities In Patients Receiving Vectibix(R) (Panitumumab)

Amgen (NASDAQ: AMGN) announced updated results from the "STEPP" (Skin Toxicity Evaluation Protocol with Panitumumab) trial, the first prospective study to examine differences between preemptive and reactive skin treatment for skin toxicities in metastatic colorectal cancer (mCRC) patients receiving epidermal growth factor receptor (EGFr) therapy.

Bowel Cancer Patients Live Longer Taking Xeloda - Analysis Confirms That Oral Xeloda Is Superior To IV 5-FU

A pre-planned multivariate analysis of the five-year follow-up data shows that patients receiving chemotherapy after-surgery to treat colon cancer, are more likely to live longer when taking the chemotherapy pill Xeloda (capecitabine), compared to those receiving 5-FU/FA intravenous (IV) chemotherapy. The study compared Xeloda to the previous gold-standard IV chemotherapy for colon cancer, 5-FU/FA*, also known as the Mayo Clinic regimen.

Chemotherapy Resistance Overcome In The Lab Using Re-Purposed Malaysian Folk Medication

Researchers from McGill University's Faculty of Medicine have discovered a compound that reduces resistance to chemotherapy agents used to treat cancer. Their results were published in the June issue of The Journal of Clinical Investigation (JCI). Dr.

Gregory Videtic, MD, CM, FRCPC, Inducted into Cambridge Who’s Who Executive, Professional and Entrepreneurial Registry

Dr. Videtic has 22 years of experience in his profession. He is considered an expert in treating patients with thoracic malignancies and on a daily basis is responsible for clinical care and conducting research.

Avalon Pharmaceuticals Names Lead Development Candidate In Beta-Catenin Inhibitor Program

Avalon Pharmaceuticals, Inc. (Nasdaq: AVRX), has announced the nomination of AVN316 as a lead clinical development candidate in its Beta-catenin Pathway Inhibitor program. This novel compound inhibits the Beta-catenin pathway and is a potent inducer of cancer cell death. The Company plans to begin clinical testing of AVN316 in patients in 2009.

Metastatic Colon Cancer Research Benefits From $1.8M Award

Through the generous philanthropic support of the Littlefield 2000 Trust, the American Association for Cancer Research (AACR) is pleased to announce three recipients of the 2008 Jeannik M. Littlefield-AACR Grants for Metastatic Colon Cancer Research, totaling $1.8 million. In its third year, this competitive funding program is focused on high impact grants to accelerate the discovery and development of new treatments for metastatic colon cancer.

Poverty, Poor Health Might Influence Colorectal Cancer Screening Attendance

Patients who believe in the value of colorectal cancer screenings and fear cancer often say they would undergo preventive testing, but their intentions do not necessarily translate into action, according to a new study. "It's well known that people don't always do what they say they're going to do," said Emily Power, lead author.

Global Vaccine Alliance Board Approves $3.5B Investment Strategy That Includes HPV Vaccine

The board of the Global Alliance for Vaccines and Immunisation (GAVI) -- a public-private partnership that invests in childhood vaccinations in developing countries -- endorsed a $3.5 billion vaccine investment

FDA Delays Approval Of Mercks HPV Vaccine Gardasil For Older Women

FDA has delayed a decision on Merck's application to expand marketing of its human papillomavirus vaccine Gardasil to women ages 27 to 45, the company said Wednesday, the Newark Star-Ledger reports (Newark Star-Ledger, 6/26).

Avastin(R) Shows Unprecedented Benefits In Colorectal Cancer Patients, Irrespective Of K-Ras Gene Mutation

Data presented at the 10th World Congress on Gastrointestinal Cancer (WCGC) in Barcelona confirm that Avastin (bevacizumab) significantly improves survival in patients with metastatic colorectal cancer regardless of whether they have mutation in a gene known as K-Ras. This outcome is important because other biologic combinations have been found to be ineffective in patients with a mutation in the K-Ras gene, which is found in up to half of patients with colorectal cancer.

Next Page »